This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The dry powder inhaler market size has grown strongly in recent years. It will grow from $21.25 billion in 2024 to $22.35 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to renewed interest in sustainable building materials, cultural preservation and heritage restoration, rise in green building practices, local sourcing and community involvement, regulatory support and building codes.
The dry powder inhaler market size is expected to see steady growth in the next few years. It will grow to $27.13 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to continued emphasis on sustainability, global urbanization trends, advancements in manufacturing processes, government incentives and policies, global economic factors. Major trends in the forecast period include increased research and development, renewed interest in traditional building techniques, advancements in material technology, architectural and design trends, regulatory support for sustainable construction.
The increasing prevalence of respiratory diseases is anticipated to boost the growth of the dry powder inhaler market in the future. Respiratory diseases encompass a wide range of disorders affecting the respiratory system, including various lung diseases. Dry powder inhalers play a critical role in treating respiratory conditions such as asthma, COPD, and cystic fibrosis by delivering medication directly to the lungs, where it is most effective. This method serves as a promising alternative to traditional drug delivery techniques for respiratory issues. For example, a study published in December 2023 by JAMA Network Open, a medical journal of the American Medical Association, indicates that the global burden of chronic obstructive pulmonary disease (COPD) is projected to nearly reach 600 million cases worldwide by 2050, reflecting a 23% increase in prevalence. Notably, cases among females are expected to surge by 47.1%, while male cases are projected to rise by only 9.4%. Additionally, the majority of these cases are expected to occur in low- and middle-income regions, where the prevalence is anticipated to be more than double that of high-income areas by 2050. Consequently, the growing prevalence of respiratory diseases will significantly drive the expansion of the dry powder inhaler market.
The increasing levels of air pollution are also anticipated to contribute to the growth of the dry powder inhaler market. Air pollution, measured by the concentration of various pollutants in the atmosphere, leads to respiratory issues, making dry powder inhalers a preferred delivery method for medications that alleviate symptoms and manage respiratory conditions exacerbated by airborne pollutants. In 2022, the United States Environmental Protection Agency reported approximately 66 million tons of pollutants released into the atmosphere in the United States. Additionally, in March 2023, IQAir reported that Iraq was the second most polluted country with 80.1 µg/m3, 16 times higher than the WHO PM2.5 annual guideline in 2022. Therefore, the rising levels of air pollution are expected to drive the growth of the dry powder inhaler market.
Key players in the dry powder inhaler market are focusing on developing innovative products featuring muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD) while also expanding their product portfolios. Muscarinic antagonists are drugs that inhibit the muscarinic acetylcholine receptor, and they are used to manage various conditions, including COPD and organophosphate poisoning. For example, in March 2024, Berry Global, a US-based company recognized for its development and manufacturing of diverse flexible packaging solutions, unveiled its new dry powder inhaler at Pharma Pack. This inhaler is specifically designed to improve drug delivery for respiratory conditions such as COPD and asthma, providing a customizable solution for pharmaceutical companies.
In August 2024, Aptar Pharma, a US-based specialist in drug delivery, acquired the Orbital Dry Powder Inhaler for an undisclosed sum. This acquisition strengthens Aptar's capabilities in respiratory drug delivery, especially for managing conditions such as asthma and chronic obstructive pulmonary disease (COPD). The Orbital Dry Powder Inhaler is noted for its innovative design, which enhances medication delivery. This acquisition aligns with Aptar Pharma's strategy to expand its product offerings and reinforce its position in the respiratory treatment market. The Orbital DPI operates within the pharmaceutical and medical device sectors in India.
Major companies operating in the dry powder inhaler market report are Novartis AG, AstraZeneca plc., GlaxoSmithKline PLC, 3M Company, Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Catalent Inc., Aptar Group Inc., Chiesi Farmaceutici S.p.A., Recipharm AB, Cipla Limited, Lupin Limited, Orion Corporation, OPKO Health, Zhejiang Hisun Pharmaceutical Co Ltd., Beximco Pharmaceuticals Ltd., Sava Healthcare Ltd., Hovione, Elpen S.A., MannKind Corporation, Meda Pharmaceuticals, Presspart Manufacturing Ltd., SMB Laboratories SA, Teva Pharmaceutical Industries Limited, Pharmaxis Ltd., Iconovo AB, SRS Pharmaceuticals Pvt. Ltd.
North America was the largest region in the dry powder inhaler market in 2024. The regions covered in the dry powder inhaler market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the Dry Powder Inhaler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dry powder inhaler market consists of sales of dry powder forms, spiriva handihalers, breath-activated inhalers, rotahalers, diskus devices, and twisthaler inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
A dry powder inhaler (DPI) is a medical device designed for delivering medication in the form of dry powder directly to the lungs. It is primarily used for treating respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). To effectively use a DPI, it is crucial for the user to inhale rapidly and deeply, allowing the medication to reach the lungs.
The main types of dry powder inhalers include single-dose inhalers and multi-dose inhalers. Single-dose inhalers are devices that administer medication directly to the lungs in the form of dry powder. These devices can be either manually operated or digitally operated, and they find applications in treating conditions such as asthma, COPD, cystic fibrosis, and others. Various end-users, including hospitals and clinics, homecare settings, and ambulatory surgical centers, utilize these inhalers.
The dry powder inhaler market research report is one of a series of new reports that provides dry powder inhaler market statistics, including dry powder inhaler industry global market size, regional shares, competitors with a dry powder inhaler market share, detailed dry powder inhaler market segments, market trends and opportunities, and any further data you may need to thrive in the dry powder inhaler industry. This dry powder inhaler market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The dry powder inhaler market size has grown strongly in recent years. It will grow from $21.25 billion in 2024 to $22.35 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to renewed interest in sustainable building materials, cultural preservation and heritage restoration, rise in green building practices, local sourcing and community involvement, regulatory support and building codes.
The dry powder inhaler market size is expected to see steady growth in the next few years. It will grow to $27.13 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to continued emphasis on sustainability, global urbanization trends, advancements in manufacturing processes, government incentives and policies, global economic factors. Major trends in the forecast period include increased research and development, renewed interest in traditional building techniques, advancements in material technology, architectural and design trends, regulatory support for sustainable construction.
The increasing prevalence of respiratory diseases is anticipated to boost the growth of the dry powder inhaler market in the future. Respiratory diseases encompass a wide range of disorders affecting the respiratory system, including various lung diseases. Dry powder inhalers play a critical role in treating respiratory conditions such as asthma, COPD, and cystic fibrosis by delivering medication directly to the lungs, where it is most effective. This method serves as a promising alternative to traditional drug delivery techniques for respiratory issues. For example, a study published in December 2023 by JAMA Network Open, a medical journal of the American Medical Association, indicates that the global burden of chronic obstructive pulmonary disease (COPD) is projected to nearly reach 600 million cases worldwide by 2050, reflecting a 23% increase in prevalence. Notably, cases among females are expected to surge by 47.1%, while male cases are projected to rise by only 9.4%. Additionally, the majority of these cases are expected to occur in low- and middle-income regions, where the prevalence is anticipated to be more than double that of high-income areas by 2050. Consequently, the growing prevalence of respiratory diseases will significantly drive the expansion of the dry powder inhaler market.
The increasing levels of air pollution are also anticipated to contribute to the growth of the dry powder inhaler market. Air pollution, measured by the concentration of various pollutants in the atmosphere, leads to respiratory issues, making dry powder inhalers a preferred delivery method for medications that alleviate symptoms and manage respiratory conditions exacerbated by airborne pollutants. In 2022, the United States Environmental Protection Agency reported approximately 66 million tons of pollutants released into the atmosphere in the United States. Additionally, in March 2023, IQAir reported that Iraq was the second most polluted country with 80.1 µg/m3, 16 times higher than the WHO PM2.5 annual guideline in 2022. Therefore, the rising levels of air pollution are expected to drive the growth of the dry powder inhaler market.
Key players in the dry powder inhaler market are focusing on developing innovative products featuring muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD) while also expanding their product portfolios. Muscarinic antagonists are drugs that inhibit the muscarinic acetylcholine receptor, and they are used to manage various conditions, including COPD and organophosphate poisoning. For example, in March 2024, Berry Global, a US-based company recognized for its development and manufacturing of diverse flexible packaging solutions, unveiled its new dry powder inhaler at Pharma Pack. This inhaler is specifically designed to improve drug delivery for respiratory conditions such as COPD and asthma, providing a customizable solution for pharmaceutical companies.
In August 2024, Aptar Pharma, a US-based specialist in drug delivery, acquired the Orbital Dry Powder Inhaler for an undisclosed sum. This acquisition strengthens Aptar's capabilities in respiratory drug delivery, especially for managing conditions such as asthma and chronic obstructive pulmonary disease (COPD). The Orbital Dry Powder Inhaler is noted for its innovative design, which enhances medication delivery. This acquisition aligns with Aptar Pharma's strategy to expand its product offerings and reinforce its position in the respiratory treatment market. The Orbital DPI operates within the pharmaceutical and medical device sectors in India.
Major companies operating in the dry powder inhaler market report are Novartis AG, AstraZeneca plc., GlaxoSmithKline PLC, 3M Company, Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Catalent Inc., Aptar Group Inc., Chiesi Farmaceutici S.p.A., Recipharm AB, Cipla Limited, Lupin Limited, Orion Corporation, OPKO Health, Zhejiang Hisun Pharmaceutical Co Ltd., Beximco Pharmaceuticals Ltd., Sava Healthcare Ltd., Hovione, Elpen S.A., MannKind Corporation, Meda Pharmaceuticals, Presspart Manufacturing Ltd., SMB Laboratories SA, Teva Pharmaceutical Industries Limited, Pharmaxis Ltd., Iconovo AB, SRS Pharmaceuticals Pvt. Ltd.
North America was the largest region in the dry powder inhaler market in 2024. The regions covered in the dry powder inhaler market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the Dry Powder Inhaler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dry powder inhaler market consists of sales of dry powder forms, spiriva handihalers, breath-activated inhalers, rotahalers, diskus devices, and twisthaler inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
A dry powder inhaler (DPI) is a medical device designed for delivering medication in the form of dry powder directly to the lungs. It is primarily used for treating respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). To effectively use a DPI, it is crucial for the user to inhale rapidly and deeply, allowing the medication to reach the lungs.
The main types of dry powder inhalers include single-dose inhalers and multi-dose inhalers. Single-dose inhalers are devices that administer medication directly to the lungs in the form of dry powder. These devices can be either manually operated or digitally operated, and they find applications in treating conditions such as asthma, COPD, cystic fibrosis, and others. Various end-users, including hospitals and clinics, homecare settings, and ambulatory surgical centers, utilize these inhalers.
The dry powder inhaler market research report is one of a series of new reports that provides dry powder inhaler market statistics, including dry powder inhaler industry global market size, regional shares, competitors with a dry powder inhaler market share, detailed dry powder inhaler market segments, market trends and opportunities, and any further data you may need to thrive in the dry powder inhaler industry. This dry powder inhaler market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Dry Powder Inhaler Market Characteristics3. Dry Powder Inhaler Market Trends and Strategies4. Dry Powder Inhaler Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Covid and Recovery on the Market32. Global Dry Powder Inhaler Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Dry Powder Inhaler Market34. Recent Developments in the Dry Powder Inhaler Market
5. Global Dry Powder Inhaler Growth Analysis and Strategic Analysis Framework
6. Dry Powder Inhaler Market Segmentation
7. Dry Powder Inhaler Market Regional and Country Analysis
8. Asia-Pacific Dry Powder Inhaler Market
9. China Dry Powder Inhaler Market
10. India Dry Powder Inhaler Market
11. Japan Dry Powder Inhaler Market
12. Australia Dry Powder Inhaler Market
13. Indonesia Dry Powder Inhaler Market
14. South Korea Dry Powder Inhaler Market
15. Western Europe Dry Powder Inhaler Market
16. UK Dry Powder Inhaler Market
17. Germany Dry Powder Inhaler Market
18. France Dry Powder Inhaler Market
19. Italy Dry Powder Inhaler Market
20. Spain Dry Powder Inhaler Market
21. Eastern Europe Dry Powder Inhaler Market
22. Russia Dry Powder Inhaler Market
23. North America Dry Powder Inhaler Market
24. USA Dry Powder Inhaler Market
25. Canada Dry Powder Inhaler Market
26. South America Dry Powder Inhaler Market
27. Brazil Dry Powder Inhaler Market
28. Middle East Dry Powder Inhaler Market
29. Africa Dry Powder Inhaler Market
30. Dry Powder Inhaler Market Competitive Landscape and Company Profiles
31. Dry Powder Inhaler Market Other Major and Innovative Companies
35. Dry Powder Inhaler Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Dry Powder Inhaler Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on dry powder inhaler market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for dry powder inhaler? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dry powder inhaler market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Single-Dose Inhalers; Multi-Dose Inhalers2) By Function: Manually Operated Inhaler Devices; Digitally Operated Inhaler Devices
3) By Application: Asthma; Chronic Obstructive Pulmonary Disease (COPD); Cystic Fibrosis; Other Applications
4) By End User: Hospitals And Clinics; Homecare Settings; Ambulatory Surgical Centers; Other End Users
Subsegments:
1) By Single-Dose Inhalers: Capsule-Based Inhalers; Diskus-Based Inhalers2) By Multi-Dose Inhalers: Blister-Based Inhalers; Rotahaler-Based Inhalers
Key Companies Mentioned: Novartis AG; AstraZeneca plc.; GlaxoSmithKline Plc; 3M Company; Boehringer Ingelheim GmbH
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Dry Powder Inhaler market report include:- Novartis AG
- AstraZeneca plc.
- GlaxoSmithKline Plc
- 3M Company
- Boehringer Ingelheim GmbH
- Viatris (Mylan N.V)
- Otsuka Pharmaceutical Co. Ltd
- Sun Pharmaceutical Industries Limited
- Catalent Inc.
- Aptar Group Inc.
- Chiesi Farmaceutici S.p.A.
- Recipharm AB
- Cipla Limited
- Lupin Limited
- Orion Corporation
- OPKO Health
- Zhejiang Hisun Pharmaceutical Co Ltd
- Beximco Pharmaceuticals Ltd
- Sava Healthcare Ltd.
- Hovione
- Elpen S.A.
- MannKind Corporation
- Meda Pharmaceuticals
- Presspart Manufacturing Ltd
- SMB Laboratories SA
- Teva Pharmaceutical Industries Limited
- Pharmaxis Ltd.
- Iconovo AB
- SRS Pharmaceuticals Pvt. Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | March 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 22.35 Billion |
Forecasted Market Value ( USD | $ 27.13 Billion |
Compound Annual Growth Rate | 5.0% |
Regions Covered | Global |
No. of Companies Mentioned | 30 |